Related Experiment Videos
Almitrine-Raubasine combination for dementia
Weimin Yang1, Ming Liu, Junfang Teng
1Department of Neurology, First Affiliated Hospital, Zhengzhou University, No. 1, Jinshe Road East, Zhengzhou, Henan Province, China, 450052.
The Cochrane Database of Systematic Reviews
|March 18, 2011
Summary
Almitrine-raubasine combination (Duxil) showed a potential benefit for cognitive function in dementia patients. However, due to low-quality trials and limited data, its routine use is not yet supported.
Area of Science:
- Neurology
- Pharmacology
Background:
- Almitrine-raubasine combination (Duxil) has been explored as a potential treatment for dementia.
- Dementia is a progressive condition affecting cognitive function and daily living.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Duxil for dementia treatment.
- To synthesize evidence from randomized controlled trials on Duxil's use in dementia.
Main Methods:
- A systematic search was conducted across multiple databases (Cochrane, CBM-disc, CNKI, Stroke Trials Registry) up to December 2009.
- Included were randomized controlled trials (RCTs) of Duxil for dementia, regardless of publication status or language.
- Data extraction and quality assessment were performed independently by two reviewers.
Main Results:
- Three trials with 206 participants, all diagnosed with vascular dementia, were included.
- Duxil demonstrated a significant beneficial effect on cognitive function (MMSE) (WMD 2.04, 95% CI 1.43 to 2.66).
- No significant improvement in functional performance (ADL) was observed (WMD -1.68; 95% CI -3.70 to 0.35), and adverse events did not differ significantly.
Conclusions:
- The included trials were of low methodological quality, with a small sample size and potential publication bias.
- Insufficient evidence exists to recommend the routine use of Duxil for dementia treatment.
- High-quality, large-scale RCTs are necessary to validate these findings.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...